7,8-dihydro-6-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid | 89781-66-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7,8-dihydro-6-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid
• 英文别名: 1,2-dihydro-3-(1-imidazolyl)-7-carboxynaphthalene；6-(1H-Imidazol-1-yl)-7,8-dihydro-2-naphthalenecarboxylic acid；6-imidazol-1-yl-7,8-dihydronaphthalene-2-carboxylic acid
• CAS: 89781-66-8
• 化学式: C₁₄H₁₂N₂O₂
• 分子量: 240.261
• InChiKey: LUUULRLWYJEWOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  481.1±55.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(6-溴-3,4-二氢萘-2-基)咪唑 在 盐酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 7,8-dihydro-6-(1H-imidazol-1-yl)-2-naphthalenecarboxylic acid
  参考文献：
  名称：

  N-imidazolyl derivatives of the napththalene and chroman rings as thromboxane A2 synthase inhibitors

  摘要：

  A series of N-imidazol-1-yl derivatives of 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthalene, 2H-1-benzopyran and some related compounds were synthesized and tested as inhibitors of thromboxane A2 synthase in ex vivo experiments with orally treated rats. Some compounds showed good activity which was confirmed in experiments in vitro in rabbit whole blood. Some structural requirements for significant TxA2 synthase inhibitory activity are discussed. The selected 5,6-Dihydro-7-(H-1-imidazol-1-yl)-2-naphthalene-carboxylic acid (compound 7) was conformationally analysed using the Sybyl molecular model system in comparison with dazoxiben. Compound 7 was further pharmacologically investigated and on the basis of its interesting activities in vitro, ex vivo and in vivo and its low toxicity was selected for clinical investigation.

  DOI：

  10.1016/0223-5234(91)90103-t

文献信息

• [EN] PHARMACEUTICAL COMPOSITION CONTAINING AN ACE INHIBITOR AND AN INHIBITOR OF THROMBOXANE A2 ACTIVITY FOR TREATING NEPHROPATHIES
  申请人：FARMITALIA CARLO ERBA SRL

  公开号：WO1992006713A1

  公开（公告）日：1992-04-30

  (EN) A pharmaceutical composition containing an angiotensin converting enzyme inhibitor and an inhibitor of thromboxane A2 activity, or a pharmaceutically acceptable salt thereof, is useful in the treatment of nephropathies and hyperlipidaemia secondary to nephrotic syndrome.(FR) Composition pharmaceutique contenant un inhibiteur de l'enzyme de conversion de l'angiotensine (ECA) et un inhibiteur de l'activité de la thromboxane A2, ou un sel pharmaceutiquement acceptable de ces agents, utile pour le traitement de néphropathies et d'hyperlipidémies complémentaires au syndrome néphrotique.

  一种含有血管紧张素转换酶抑制剂和血栓素A2活性抑制剂或其药学上可接受的盐的药物组合物，适用于治疗肾病和由肾病综合征引起的高脂血症。
• COMBINED USE OF N-IMIDAZOLYL DERIVATIVES OF BICYCLIC COMPOUNDS AND CYCLOSPORINE IN THERAPY
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0433427A1

  公开（公告）日：1991-06-26
• PHARMACEUTICAL COMPOSITION CONTAINING AN ACE INHIBITOR AND AN INHIBITOR OF THROMBOXANE A2 ACTIVITY FOR TREATING NEPHROPATHIES
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0556204A1

  公开（公告）日：1993-08-25
• US4510149A
  申请人：——

  公开号：US4510149A

  公开（公告）日：1985-04-09
• US4602022A
  申请人：——

  公开号：US4602022A

  公开（公告）日：1986-07-22